Brilinta regulatory update

AstraZeneca said China's State Food and Drug Administration (SFDA) approved Brilinta ticagrelor prevent thrombotic cardiovascular events in patients with acute coronary syndromes (ACS). The pharma said the product will be immediately available for physicians to prescribe in China, but it will launch it with full promotional efforts next half. ...